Drug Discovery for Menopause with Gero and AthenaBIO
athenadao.substack.com · 1,720 words · saved by 1 readers
Pharma’s Blind Spot
Dr. Peter Fedichev is the Co-Founder and CEO of Gero, an AI-driven biotech company focused on drug discovery. In January of 2025, AthenaBIO funded a program to focus on menopause following a fortuitous meeting with Dr. Fedichev at JPM Week the previous year. Since then, Gero inked a $250M deal with Roche’s Chugai and has raised a further $23M, with Dr. Fedichev being named a World Economic Forum tech pioneer. Q: You are a longevity drug discovery biotech. How did you get interested in menopause? Our interest in women’s health, and menopause in particular, actually began as a technical…
saved by
related reading
- Menopause Delayfertilitypreservation.org
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- What the Aging Field Needs - Celine Haliouacelinehh.com
- Rebuild Biotech for the AI Era | Benchlingbenchling.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Levers for Biological Progress - by Niko McCartyasimov.press
- AI Versus Eroom's Lawsubstack.com
- Amaranth Foundation - Longevity and Neuroscienceamaranth.foundation
- A billion years of evolution in a single afternoon — George Churchdwarkesh.com
- The “Stepping Stone” Approach to Getting Longevity Drugs to Market - proto.lifeproto.life
- AI After Drug Developmentasteriskmag.substack.com
- Curie.Biocurie.bio